Portal de Periódicos da CAPES

Update in Rheumatology: Evidence Published in 2016

2017; American College of Physicians; Volume: 166; Issue: 7 Linguagem: Inglês

10.7326/m17-0115

1539-3704

E. Blair Solow, Shannon Scielzo, Salahuddin Kazi,

Pharmaceutical studies and practices

Updates4 April 2017Update in Rheumatology: Evidence Published in 2016E. Blair Solow, MD, MSCS, Shannon A. Scielzo, PhD, and Salahuddin Kazi, MDE. Blair Solow, MD, MSCSFrom the University of Texas Southwestern Medical Center at Dallas, Dallas, Texas.Search for more papers by this author, Shannon A. Scielzo, PhDFrom the University of Texas Southwestern Medical Center at Dallas, Dallas, Texas.Search for more papers by this author, and Salahuddin Kazi, MDFrom the University of Texas Southwestern Medical Center at Dallas, Dallas, Texas.Search for more papers by this authorAuthor, Article, and Disclosure Informationhttps://doi.org/10.7326/M17-0115 SectionsAboutFull TextPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissions ShareFacebookTwitterLinkedInRedditEmail In this year's Update in Rheumatology, we review articles within the themes of high-value care, systems-level optimization, risk stratification in patients with autoimmunity, and breakthroughs in treatment strategies. We searched the medical literature by using PubMed and rheumatic disease keywords for the calendar year 2016. We reviewed the abstracts independently and scored the articles on the basis of their relevance to internists and the validity of the methods.Eight articles are presented in this update, starting with 3 studies on risk stratification in patients with autoimmunity. Nonsteroidal anti-inflammatory drugs (NSAIDs), including celecoxib, are associated with a higher risk for cardiovascular ... Author, Article, and Disclosure InformationAffiliations: From the University of Texas Southwestern Medical Center at Dallas, Dallas, Texas.Disclosures: Dr. Kazi reports that he serves on the American Board of Internal Medicine Rheumatology Board and is the chair of the American College of Rheumatology's Registries and Health Information Technology Committee. Authors not named here have disclosed no conflicts of interest. Forms can be viewed at www.acponline.org/authors/icmje/ConflictOfInterestForms.do?msNum=M17-0115.Corresponding Author: E. Blair Solow, MD, MSCS, Division of Rheumatic Diseases, Department of Internal Medicine, UT Southwestern Medical Center at Dallas, 5323 Harry Hines Boulevard, Mail Code 8884, Dallas, TX 75390; e-mail, elizabeth.[email protected]edu.Current Author Addresses: Drs. Solow, Scielzo, and Kazi: Department of Internal Medicine, UT Southwestern Medical Center at Dallas, 5323 Harry, Hines Boulevard, Dallas, TX 75390.Author Contributions: Conception and design: S. Kazi, S.A. Scielzo, E.B. Solow.Analysis and interpretation of the data: S. Kazi, S.A. Scielzo, E.B. Solow.Drafting of the article: S. Kazi, S.A. Scielzo, E.B. Solow.Critical revision for important intellectual content: S. Kazi, E.B. Solow.Final approval of the article: S. Kazi, S.A. Scielzo, E.B. Solow.Statistical expertise: S.A. Scielzo.Collection and assembly of data: S. Kazi, S.A. Scielzo, E.B. Solow.This article was published at Annals.org on 30 March 2017. PreviousarticleNextarticle Advertisement FiguresReferencesRelatedDetails Metrics 4 April 2017Volume 166, Issue 7Page: W44-W47KeywordsDisease modifying antirheumatic drugsFood and Drug AdministrationIbuprofenMonoclonal antibodiesMortalityRheumatoid arthritisRheumatologySafetyStatinsVaccines ePublished: 30 March 2017 Issue Published: 4 April 2017 Copyright & PermissionsCopyright © 2017 by American College of Physicians. All Rights Reserved.PDF downloadLoading ...